• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    EXL Announces Appointment of Andreas Fibig to Board of Directors

    1/12/23 4:01:00 PM ET
    $EXLS
    $IFF
    $NVO
    Real Estate
    Real Estate
    Major Chemicals
    Industrials
    Get the next $EXLS alert in real time by email

    NEW YORK, Jan. 12, 2023 (GLOBE NEWSWIRE) -- ExlService Holdings, Inc. (NASDAQ:EXLS), a leading global data analytics and digital operations and solutions company, today announced that Andreas Fibig, a seasoned global executive with a strong record of innovation across industries and geographies, has been appointed to EXL's Board of Directors as an independent director effective Jan. 10, 2023. Fibig will be a member of the Board's Audit and Nominating and Governance Committees.

    "Andreas is a distinguished global business leader with more than 25 years of international health care, pharmaceutical, and consumer industry experience," said Vikram S. Pandit, Chairman of the Board of EXL. "We look forward to the insights and contributions Andreas will bring to the Board and leadership team as the company executes on its growth strategy."

    EXL Vice Chairman and Chief Executive Officer Rohit Kapoor said, "We are delighted to welcome Andreas to our Board of Directors. His years of experience leading large global organizations will provide us with valuable insight and perspective as we rapidly scale EXL into the dominant global player in analytics and digital operations. Andreas also brings a unique combination of experience in international markets along with a deep understanding of U.S. business, which will benefit EXL as we continue our geographic expansion, particularly in Europe."

    "I'm truly excited to join the EXL Board at this stage in the company's journey," said Fibig. "EXL's transformation to a data-led analytics and digital operations company has resulted in remarkable growth and significant improvement in profitability. I look forward to working with the Board and management team to help the company continue its growth trajectory as well as create sustainable competitive advantage through its digital strategy. I am also honored to be part of an organization that focuses on sustainability as part of its enterprise strategy, and I'm excited to help further those efforts."

    Fibig spent 10 years with International Flavors & Fragrances (NYSE:IFF), an industry leader in food ingredients, beverage, scent, health care and biosciences, including seven years as Chairman and CEO. There, he established a record of driving strong growth as well as leading the company through significant transformation, including the integration of DuPont Nutrition & Biosciences following a merger. Prior to that, he served as president and chairman of the board of management for Bayer Health Care Pharmaceuticals, where he was the chief executive responsible for Bayer's global health care and pharmaceutical business. He currently serves on the board of Novo-Nordisk A/S (NYSE:NVO), where he is an independent director and member of the Research and Development Committee. He also serves as a director of Indigo Agriculture and EvodiaBio, which are private companies. He previously served on the board of Bunge Limited, a leading global agribusiness and food company.

    About EXL

    EXL (NASDAQ:EXLS) is a leading data analytics and digital operations and solutions company that partners with clients to improve business outcomes and unlock growth. By bringing together deep domain expertise with robust data, powerful analytics, cloud, artificial intelligence ("AI") and machine learning ("ML"), we create agile, scalable solutions and execute complex operations for the world's leading corporations in industries including insurance, healthcare, banking and financial services, media, and retail, among others. Focused on driving faster decision-making and transforming operating models, EXL was founded on the core values of innovation, collaboration, excellence, integrity and respect. Headquartered in New York, our team is over 43,100 strong, with more than 50 offices spanning six continents. For more information, visit www.exlservice.com.

    Cautionary Statement Regarding Forward-Looking Statements

    This press release contains forward-looking statements. You should not place undue reliance on those statements because they are subject to numerous uncertainties and factors relating to EXL's operations and business environment, all of which are difficult to predict and many of which are beyond EXL's control. Forward-looking statements include information concerning EXL's possible or assumed future results of operations, including descriptions of its business strategy. These statements may include words such as "may," "will," "should," "believe," "expect," "anticipate," "intend," "plan," "estimate" or similar expressions. These statements are based on assumptions that we have made in light of management's experience in the industry as well as its perceptions of historical trends, current conditions, expected future developments and other factors it believes are appropriate under the circumstances. You should understand that these statements are not guarantees of performance or results. They involve known and unknown risks, uncertainties and assumptions. Although EXL believes that these forward-looking statements are based on reasonable assumptions, you should be aware that many factors could affect EXL's actual financial results or results of operations and could cause actual results to differ materially from those in the forward-looking statements. These factors, which include our ability to successfully close and integrate strategic acquisitions, our ability to respond to and manage public health crises, including the outbreak and continued effects of COVID-19 pandemic, are discussed in more detail in EXL's filings with the Securities and Exchange Commission, including EXL's Quarterly Report on Form 10-Q and Annual Report on Form 10-K. These risks could cause actual results to differ materially from those implied by forward-looking statements in this release. You should keep in mind that any forward-looking statement made herein, or elsewhere, speaks only as of the date on which it is made. New risks and uncertainties come up from time to time, and it is impossible to predict these events or how they may affect EXL. EXL has no obligation to update any forward-looking statements after the date hereof, except as required by federal securities laws.

    © 2023 ExlService Holdings, Inc. All rights reserved. For more information go to www.exlservice.com/legal-disclaimer

    Contacts

    Media 

    Keith Little

    Senior Manager, Media Relations

    +1 703-598-0980 

    keith.little@exlservice.com

    Investor Relations

    John Kristoff

    +1 212 209 4613

    IR@exlservice.com



    Primary Logo

    Get the next $EXLS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EXLS
    $IFF
    $NVO

    CompanyDatePrice TargetRatingAnalyst
    Novo Nordisk A/S
    $NVO
    3/26/2026Peer Perform
    Wolfe Research
    Novo Nordisk A/S
    $NVO
    3/18/2026Underperform
    Bernstein
    Novo Nordisk A/S
    $NVO
    3/18/2026$175.00Outperform
    Bernstein
    Novo Nordisk A/S
    $NVO
    3/10/2026$42.00Buy → Hold
    TD Cowen
    Novo Nordisk A/S
    $NVO
    3/3/2026$40.00Underweight → Equal-Weight
    Morgan Stanley
    Novo Nordisk A/S
    $NVO
    3/2/2026$41.00Buy → Neutral
    Goldman
    Novo Nordisk A/S
    $NVO
    2/24/2026Buy → Hold
    Kepler
    Novo Nordisk A/S
    $NVO
    2/24/2026Overweight → Neutral
    Analyst
    More analyst ratings

    $EXLS
    $IFF
    $NVO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    March 8, 2024 - FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight

    For Immediate Release: March 08, 2024 Today, the U.S. Food and Drug Administration approved a new indication for use for Wegovy (semaglutide) injection to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight. Wegovy should be used in addition to a reduced calorie diet and increased physical activity. Cardiovascular disease is a gr

    3/8/24 2:00:18 PM ET
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EXLS
    $IFF
    $NVO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Fyrwald J Erik

    4 - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Issuer)

    4/3/26 4:14:20 PM ET
    $IFF
    Major Chemicals
    Industrials

    SEC Form 4 filed by Finzel Ralf

    4 - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Issuer)

    4/3/26 4:14:18 PM ET
    $IFF
    Major Chemicals
    Industrials

    SEC Form 4 filed by Birenkrant Marc

    4 - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Issuer)

    4/3/26 4:13:16 PM ET
    $IFF
    Major Chemicals
    Industrials

    $EXLS
    $IFF
    $NVO
    SEC Filings

    View All

    SEC Form 6-K filed by Novo Nordisk A/S

    6-K - NOVO NORDISK A S (0000353278) (Filer)

    3/30/26 9:05:01 AM ET
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Novo Nordisk A/S

    6-K - NOVO NORDISK A S (0000353278) (Filer)

    3/27/26 7:47:17 AM ET
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Novo Nordisk A/S

    6-K - NOVO NORDISK A S (0000353278) (Filer)

    3/27/26 6:33:06 AM ET
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EXLS
    $IFF
    $NVO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research initiated coverage on Novo Nordisk A/S

    Wolfe Research initiated coverage of Novo Nordisk A/S with a rating of Peer Perform

    3/26/26 9:00:52 AM ET
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bernstein initiated coverage on Novo Nordisk A/S

    Bernstein initiated coverage of Novo Nordisk A/S with a rating of Underperform

    3/18/26 3:58:44 PM ET
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bernstein initiated coverage on Novo Nordisk A/S with a new price target

    Bernstein initiated coverage of Novo Nordisk A/S with a rating of Outperform and set a new price target of $175.00

    3/18/26 1:57:24 PM ET
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EXLS
    $IFF
    $NVO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Fribourg Paul J bought $10,971,329 worth of shares (156,459 units at $70.12) and sold $14,481 worth of shares (222 units at $65.23), increasing direct ownership by 92% to 29,650 units (SEC Form 4)

    4 - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Issuer)

    3/16/26 4:33:49 PM ET
    $IFF
    Major Chemicals
    Industrials

    Chief Executive Officer Fyrwald J Erik bought $995,204 worth of shares (14,260 units at $69.79), increasing direct ownership by 18% to 91,630 units (SEC Form 4)

    4 - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Issuer)

    3/16/26 4:33:47 PM ET
    $IFF
    Major Chemicals
    Industrials

    EVP, General Counsel Landsman Stephen N bought $196,788 worth of shares (3,100 units at $63.48), increasing direct ownership by 26% to 15,100 units (SEC Form 4)

    4 - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Issuer)

    12/12/25 4:18:29 PM ET
    $IFF
    Major Chemicals
    Industrials

    $EXLS
    $IFF
    $NVO
    Leadership Updates

    Live Leadership Updates

    View All

    Data and AI Leader EXL to host 'IdeaTank' innovation event at the Nasdaq MarketSite

    More than 11,000 pitch ideas submitted from EXL employees globally Shark Tank's Robert Herjavec to join EXL IdeaTank event NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- EXL (NASDAQ:EXLS), a global data and AI company, announced that it will hold its second annual IdeaTank event at the Nasdaq MarketSite on December 8, 2025. A celebration of EXL's innovation-at-speed culture and AI-native workforce, the event features new data and AI pitch ideas submitted from EXL's global employee base. Winning ideas receive funding and fast-track development resources to launch new capabilities and breakthrough client solutions. Now in its second year, the 2025 IdeaTank has received more than 11,000 submi

    11/25/25 2:26:35 PM ET
    $EXLS
    Real Estate

    Mativ Announces Appointment of Seasoned Executive to Its Board of Directors

    Deborah Borg Brings 25+ Years of Corporate Leadership to Global Manufacturing Leader Mativ Holdings, Inc. (NYSE:MATV) announced today the appointment of Deborah Borg to its Board of Directors, effective immediately. In her role on the Mativ Board of Directors, Borg will serve on the Company's Compensation Committee and Nominating & Governance Committee. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251124104625/en/Deborah Borg, Mativ Board of Directors Borg is currently the Executive Vice President, Chief People & Culture Officer at International Flavors & Fragrances Inc. (NYSE:IFF), a global leader in food, beverage, health, b

    11/24/25 4:05:00 PM ET
    $IFF
    $MATV
    $SWM
    Major Chemicals
    Industrials
    Paper
    Basic Materials

    IFF Announces Appointment of Brett Icahn and Richard Mulligan to Board of Directors

    IFF (NYSE:IFF)—a global leader in flavors, fragrances, food ingredients, health and biosciences—today announced the appointment of Brett Icahn and Richard Mulligan, Ph.D., to its board of directors, effective Oct. 20. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022380951/en/Brett Icahn (Photo: IFF) These appointments follow the company's previously disclosed cooperation agreement with Icahn Capital LP and its affiliates. Icahn serves as the Icahn designee to the IFF board, replacing Vincent Intrieri, and Mulligan joined as the mutually agreed independent director, replacing Margarita Paláu-Hernández. Intrieri and Paláu-Her

    10/22/25 4:15:00 PM ET
    $IFF
    Major Chemicals
    Industrials

    $EXLS
    $IFF
    $NVO
    Financials

    Live finance-specific insights

    View All

    IFF Declares Dividend for First Quarter 2026

    IFF (NYSE:IFF) announced that its Board of Directors has declared a regular quarterly cash dividend of $0.40 per share of its common stock, payable on April 10, 2026 to shareholders of record as of March 20, 2026. Welcome to IFF At IFF (NYSE:IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.com, LinkedIn, Instagram and Facebook. © 2026 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights

    3/4/26 4:15:00 PM ET
    $IFF
    Major Chemicals
    Industrials

    EXL Reports 2025 Fourth Quarter and Year-End Results; Issues 2026 Guidance

    2025 Fourth Quarter Revenue of $542.6 Million, up 12.7% year-over-yearQ4 Diluted EPS (GAAP) of $0.38, up 21.8% from $0.31 in Q4 of 2024Q4 Adjusted Diluted EPS (Non-GAAP) (1) of $0.50, up 15.0% from $0.44 in Q4 of 2024 2025 Revenue of $2.09 Billion, up 13.6% year-over-year2025 Diluted EPS (GAAP) of $1.54, up 28.0% from $1.21 in 20242025 Adjusted Diluted EPS (Non-GAAP) (1) of $1.95, up 18.0% from $1.65 in 2024 NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- ExlService Holdings, Inc. (NASDAQ:EXLS), a global data and AI company, today announced its financial results for the quarter and full year ended December 31, 2025. Chairman and Chief Executive Officer Rohit Kapoor said, "I am pleased to r

    2/24/26 4:01:00 PM ET
    $EXLS
    Real Estate

    IFF Reports Fourth Quarter and Full Year 2025 Results

    Delivered solid top and bottom-line performance & advanced strategic priorities in 2025 Launched sale process for the Food Ingredients segment Continuing to drive financial performance in 2026 International Flavors & Fragrances Inc. (NYSE:IFF) reported financial results for the fourth quarter and full year ended December 31, 2025. Full year 2025 Consolidated Summary: Reported   Adjusted (GAAP) (Non-GAAP)1 Sales   Loss Before Taxes   EPS   Operating EBITDA   Operating EBITDA Margin   EPS ex Amortization $10.9 B   $(412) M   $(1.46)   $2.1 B

    2/11/26 4:15:00 PM ET
    $IFF
    Major Chemicals
    Industrials

    $EXLS
    $IFF
    $NVO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by ExlService Holdings Inc.

    SC 13G/A - ExlService Holdings, Inc. (0001297989) (Subject)

    11/12/24 9:55:17 AM ET
    $EXLS
    Real Estate

    SEC Form SC 13G/A filed by International Flavors & Fragrances Inc. (Amendment)

    SC 13G/A - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Subject)

    3/8/24 4:44:49 PM ET
    $IFF
    Major Chemicals
    Industrials

    SEC Form SC 13G/A filed by International Flavors & Fragrances Inc. (Amendment)

    SC 13G/A - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Subject)

    2/13/24 5:07:58 PM ET
    $IFF
    Major Chemicals
    Industrials

    $EXLS
    $IFF
    $NVO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    EXL announces a strategic services collaboration with Google Cloud

    NEW YORK, April 02, 2026 (GLOBE NEWSWIRE) -- EXL (NASDAQ:EXLS), a global data and AI company, announced a strategic collaboration with Google Cloud to provide services that can accelerate AI-led transformation and drive business outcomes for clients. EXL will collaborate closely with Google Cloud to help clients scale enterprise AI, turn data into strategic assets, and drive cloud modernization across priority markets and industries. This effort will help accelerate EXL's Google Cloud practice by expanding capabilities across priority sales plays, supporting global expansion into new markets, and deepening co-innovation and go-to-market execution. Through this collaboration, EXL will exp

    4/2/26 2:39:03 PM ET
    $EXLS
    Real Estate

    IFF Launches PureStrong™, a Probiotic Made Specifically for Dogs

    IFF (NYSE:IFF)—a global leader in flavors, fragrances, food ingredients and health & biosciences—is introducing PureStrong™, a new probiotic developed exclusively for canine digestive health. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260401736960/en/IFF introduces PureStrong™, a probiotic made specifically for dogs. Today, many people consider their pet dogs part of the family. This shift is fueling rapid growth in the $3.2 billion U.S. pet supplement market. With nearly half of U.S. pet owners having purchased or considering probiotics for their dogs, PureStrong™ sets a new standard: pet‑first science built specifically fo

    4/2/26 8:15:00 AM ET
    $IFF
    Major Chemicals
    Industrials

    IFF Secures First Heart Health Claim for Soy Protein in Australia and New Zealand

    Regulatory milestone opens heart health growth opportunities for food and beverage manufacturers IFF (NYSE:IFF), a global leader in flavors, fragrances, food ingredients and health & biosciences announced today that a new heart health claim for isolated soy protein has been accepted by the Food Standards Australia New Zealand (FSANZ). The approval enables food and beverage manufacturers in Australia and New Zealand to link soy protein consumption with healthy blood cholesterol levels. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330523416/en/First heart health claim approved for soy protein in Australia and New Zealand. "

    3/31/26 10:00:00 AM ET
    $IFF
    Major Chemicals
    Industrials